| Literature DB >> 27297549 |
.
Abstract
Researchers have identified additional driver mutations in non-small cell lung cancer that may guide the development of new targeted drugs and immunotherapy. The findings also highlight key differences between two major NSCLC subtypes that could inform future therapeutic strategies. ©2016 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27297549 DOI： 10.1158/2159-8290.CD-NB2016-074
Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397